SEARCH:   Advanced

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Preudhomme, C. Articles by Fenaux, P. Search for Related Content PubMed PubMed Citation Articles by Preudhomme, C. Articles by Fenaux, P. Related Collections Neoplasia Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  Blood, 15 October 2000, Vol. 96, No. 8, pp. 2862-2869 NEOPLASIA High incidence of biallelic point mutations in the Runt domain of the AML1/PEBP2B gene in Mo acute myeloid leukemia and in myeloid malignancies with acquired trisomy 21 Claude Preudhomme, Delphine Warot-Loze, Christophe Roumier, Nalthalie Grardel-Duflos, Richard Garand, Jean Luc Lai, Nicole Dastugue, Elizabeth Macintyre, Claude Denis, Francis Bauters, Jean Pierre Kerckaert, Alain Cosson, and Pierre Fenaux From the Laboratoire d'Hématologie A, Hôpital Calmette-CHU of Lille, France; Unité INSERM-U524-Lille; Laboratoire d'Hématologie-CHU of Nantes, France; Laboratoire de Cytogénétique-CHU of Lille; Laboratoire de Cytogénétique-CHU of Toulouse Purpan, France; Laboratoire d'Hématologie, Hôpital Necker-Paris, France, and Service des Maladies du Sang-CHU of Lille. The AML1 gene, situated in 21q22, is often rearranged in acute leukemias through t(8;21) translocation, t(12;21) translocation, or less often t(3;21) translocation. Recently, point mutations in the Runt domain of the AML1 gene have also been reported in leukemia patients. Observations for mutations of the Runt domain of the AML1 gene in bone marrow cells were made in 300 patients, including 131 with acute myeloid leukemia (AML), 94 with myelodysplastic syndrome (MDS), 28 with blast crisis chronic myeloid leukemia (CML), 3 with atypical CML, 41 with acute lymphoblastic leukemia (ALL), and 3 with essential thrombocythemia (ET). Forty-one of the patients had chromosome 21 abnormalities, including t(8;21) in 6 of the patients with AML, t(12;21) in 8 patients with ALL, acquired trisomy 21 in 17 patients, tetrasomy 21 in 7 patients, and constitutional trisomy 21 (Down syndrome) in 3 patients. A point mutation was found in 14 cases (4.7%), including 9 (22%) of the 41 patients with AML of the Mo type (MoAML) (none of them had detectable chromosome 21 rearrangement) and 5 (38%) of the 13 myeloid malignancies with acquired trisomy 21 (1 M1AML, 2 M2AML, 1 ET, and 1 atypical CML). In at least 8 of 9 mutated cases of MoAML, both AML alleles were mutated: 3 patients had different stop codon mutations of the 2 AML1 alleles, and 5 patients had the same missense or stop codon mutation in both AML1 alleles, which resulted in at least 3 of the patients having duplication of the mutated allele and deletion of the normal residual allele, as shown by FISH analysis and by comparing microsatellite analyses of several chromosome 21 markers on diagnosis and remission samples. In the remaining mutated cases, with acquired trisomy 21, a missense mutation of AML1, which involved 2 of the 3 copies of the AML1 gene, was found. Four of the 7 mutated cases could be reanalyzed in complete remission, and no AML1 mutation was found, showing that mutations were acquired in the leukemic clone. In conclusion, these findings confirm the possibility of mutations of the Runt domain of the AML1 gene in leukemias, mainly in MoAML and in myeloid malignancies with acquired trisomy 21. AML1 mutations, in MoAML, involved both alleles and probably lead to nonfunctional AML1 protein. As AML1 protein regulates the expression of the myeloperoxidase gene, the relationship between AML1 mutations and Mo phenotype in AML will have to be further explored. © 2000 by The American Society of Hematology.   CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: H. Huang, M. Yu, T. E. Akie, T. B. Moran, A. J. Woo, N. Tu, Z. Waldon, Y. Y. Lin, H. Steen, and A. B. Cantor Differentiation-Dependent Interactions between RUNX-1 and FLI-1 during Megakaryocyte Development Mol. Cell. Biol., August 1, 2009; 29(15): 4103 - 4115. [Abstract] [Full Text] [PDF] L. Roudaia, M. D. Cheney, E. Manuylova, W. Chen, M. Morrow, S. Park, C.-T. Lee, P. Kaur, O. Williams, J. H. Bushweller, et al. CBF{beta} is critical for AML1-ETO and TEL-AML1 activity Blood, March 26, 2009; 113(13): 3070 - 3079. [Abstract] [Full Text] [PDF] S. Malinge, S. Izraeli, and J. D. Crispino Insights into the manifestations, outcomes, and mechanisms of leukemogenesis in Down syndrome Blood, March 19, 2009; 113(12): 2619 - 2628. [Abstract] [Full Text] [PDF] C. J. Owen, C. L. Toze, A. Koochin, D. L. Forrest, C. A. Smith, J. M. Stevens, S. C. Jackson, M.-C. Poon, G. D. Sinclair, B. Leber, et al. Five new pedigrees with inherited RUNX1 mutations causing familial platelet disorder with propensity to myeloid malignancy Blood, December 1, 2008; 112(12): 4639 - 4645. [Abstract] [Full Text] [PDF] Y. Satoh, I. Matsumura, H. Tanaka, S. Ezoe, K. Fukushima, M. Tokunaga, M. Yasumi, H. Shibayama, M. Mizuki, T. Era, et al. AML1/RUNX1 Works as a Negative Regulator of c-Mpl in Hematopoietic Stem Cells J. Biol. Chem., October 31, 2008; 283(44): 30045 - 30056. [Abstract] [Full Text] [PDF] S. D. Nimer Myelodysplastic syndromes Blood, May 15, 2008; 111(10): 4841 - 4851. [Abstract] [Full Text] [PDF] N. Watanabe-Okochi, J. Kitaura, R. Ono, H. Harada, Y. Harada, Y. Komeno, H. Nakajima, T. Nosaka, T. Inaba, and T. Kitamura AML1 mutations induced MDS and MDS/AML in a mouse BMT model Blood, April 15, 2008; 111(8): 4297 - 4308. [Abstract] [Full Text] [PDF] C. Roche-Lestienne, L. Deluche, S. Corm, I. Tigaud, S. Joha, N. Philippe, S. Geffroy, J.-L. Lai, F.-E. Nicolini, C. Preudhomme, et al. RUNX1 DNA-binding mutations and RUNX1-PRDM16 cryptic fusions in BCR-ABL+ leukemias are frequently associated with secondary trisomy 21 and may contribute to clonal evolution and imatinib resistance Blood, April 1, 2008; 111(7): 3735 - 3741. [Abstract] [Full Text] [PDF] D. C. Link, G. Kunter, Y. Kasai, Y. Zhao, T. Miner, M. D. McLellan, R. E. Ries, D. Kapur, R. Nagarajan, D. C. Dale, et al. Distinct patterns of mutations occurring in de novo AML versus AML arising in the setting of severe congenital neutropenia Blood, September 1, 2007; 110(5): 1648 - 1655. [Abstract] [Full Text] [PDF] F. Dicker, C. Haferlach, W. Kern, T. Haferlach, and S. Schnittger Trisomy 13 is strongly associated with AML1/RUNX1 mutations and increased FLT3 expression in acute myeloid leukemia Blood, August 15, 2007; 110(4): 1308 - 1316. [Abstract] [Full Text] [PDF] J. Cammenga, B. Niebuhr, S. Horn, U. Bergholz, G. Putz, F. Buchholz, J. Lohler, and C. Stocking RUNX1 DNA-Binding Mutants, Associated with Minimally Differentiated Acute Myelogenous Leukemia, Disrupt Myeloid Differentiation Cancer Res., January 15, 2007; 67(2): 537 - 545. [Abstract] [Full Text] [PDF] V. Hamelin, C. Letourneux, P.-H. Romeo, F. Porteu, and M. Gaudry Thrombopoietin regulates IEX-1 gene expression through ERK-induced AML1 phosphorylation Blood, April 15, 2006; 107(8): 3106 - 3113. [Abstract] [Full Text] [PDF] M. Kundu, S. Compton, L. Garrett-Beal, T. Stacy, M. F. Starost, M. Eckhaus, N. A. Speck, and P. P. Liu Runx1 deficiency predisposes mice to T-lymphoblastic lymphoma Blood, November 15, 2005; 106(10): 3621 - 3624. [Abstract] [Full Text] [PDF] S. Frohling, C. Scholl, D. G. Gilliland, and R. L. Levine Genetics of Myeloid Malignancies: Pathogenetic and Clinical Implications J. Clin. Oncol., September 10, 2005; 23(26): 6285 - 6295. [Abstract] [Full Text] [PDF] F. Rosenbauer, S. Koschmieder, U. Steidl, and D. G. Tenen Effect of transcription-factor concentrations on leukemic stem cells Blood, September 1, 2005; 106(5): 1519 - 1524. [Abstract] [Full Text] [PDF] J. D. Growney, H. Shigematsu, Z. Li, B. H. Lee, J. Adelsperger, R. Rowan, D. P. Curley, J. L. Kutok, K. Akashi, I. R. Williams, et al. Loss of Runx1 perturbs adult hematopoiesis and is associated with a myeloproliferative phenotype Blood, July 15, 2005; 106(2): 494 - 504. [Abstract] [Full Text] [PDF] Y. Fukushima-Nakase, Y. Naoe, I. Taniuchi, H. Hosoi, T. Sugimoto, and T. Okuda Shared and distinct roles mediated through C-terminal subdomains of acute myeloid leukemia/Runt-related transcription factor molecules in murine development Blood, June 1, 2005; 105(11): 4298 - 4307. [Abstract] [Full Text] [PDF] D. P. Steensma and A. F. List Genetic Testing in the Myelodysplastic Syndromes: Molecular Insights Into Hematologic Diversity Mayo Clin. Proc., May 1, 2005; 80(5): 681 - 698. [Abstract] [PDF] J. C. Mulloy, V. Jankovic, M. Wunderlich, R. Delwel, J. Cammenga, O. Krejci, H. Zhao, P. J. M. Valk, B. Lowenberg, and S. D. Nimer AML1-ETO fusion protein up-regulates TRKA mRNA expression in human CD34+ cells, allowing nerve growth factor-induced expansion PNAS, March 15, 2005; 102(11): 4016 - 4021. [Abstract] [Full Text] [PDF] L. A. Nguyen, P. P. Pandolfi, Y. Aikawa, Y. Tagata, M. Ohki, and I. Kitabayashi Physical and functional link of the leukemia-associated factors AML1 and PML Blood, January 1, 2005; 105(1): 292 - 300. [Abstract] [Full Text] [PDF] M. L. Smith, J. D. Cavenagh, T. A. Lister, and J. Fitzgibbon Mutation of CEBPA in Familial Acute Myeloid Leukemia N. Engl. J. Med., December 2, 2004; 351(23): 2403 - 2407. [Abstract] [Full Text] [PDF] W. Sun and J. R. Downing Haploinsufficiency of AML1 results in a decrease in the number of LTR-HSCs while simultaneously inducing an increase in more mature progenitors Blood, December 1, 2004; 104(12): 3565 - 3572. [Abstract] [Full Text] [PDF] D. H. Christiansen, M. K. Andersen, and J. Pedersen-Bjergaard Mutations of AML1 are common in therapy-related myelodysplasia following therapy with alkylating agents and are significantly associated with deletion or loss of chromosome arm 7q and with subsequent leukemic transformation Blood, September 1, 2004; 104(5): 1474 - 1481. [Abstract] [Full Text] [PDF] G. Huang, K. Shigesada, H.-J. Wee, P. P. Liu, M. Osato, and Y. Ito Molecular basis for a dominant inactivation of RUNX1/AML1 by the leukemogenic inversion 16 chimera Blood, April 15, 2004; 103(8): 3200 - 3207. [Abstract] [Full Text] [PDF] H. Harada, Y. Harada, H. Niimi, T. Kyo, A. Kimura, and T. Inaba High incidence of somatic mutations in the AML1/RUNX1 gene in myelodysplastic syndrome and low blast percentage myeloid leukemia with myelodysplasia Blood, March 15, 2004; 103(6): 2316 - 2324. [Abstract] [Full Text] [PDF] Y. Imai, M. Kurokawa, Y. Yamaguchi, K. Izutsu, E. Nitta, K. Mitani, M. Satake, T. Noda, Y. Ito, and H. Hirai The Corepressor mSin3A Regulates Phosphorylation-Induced Activation, Intranuclear Location, and Stability of AML1 Mol. Cell. Biol., February 1, 2004; 24(3): 1033 - 1043. [Abstract] [Full Text] [PDF] F.-Q. Li, R. E. Person, K.-I. Takemaru, K. Williams, K. Meade-White, A. H. Ozsahin, T. Gungor, R. T. Moon, and M. Horwitz Lymphoid Enhancer Factor-1 Links Two Hereditary Leukemia Syndromes through Core-binding Factor {alpha} Regulation of ELA2 J. Biol. Chem., January 23, 2004; 279(4): 2873 - 2884. [Abstract] [Full Text] [PDF] S. Gurbuxani, P. Vyas, and J. D. Crispino Recent insights into the mechanisms of myeloid leukemogenesis in Down syndrome Blood, January 15, 2004; 103(2): 399 - 406. [Abstract] [Full Text] [PDF] M. Nishimura, Y. Fukushima-Nakase, Y. Fujita, M. Nakao, S. Toda, N. Kitamura, T. Abe, and T. Okuda VWRPY motif-dependent and -independent roles of AML1/Runx1 transcription factor in murine hematopoietic development Blood, January 15, 2004; 103(2): 562 - 570. [Abstract] [Full Text] [PDF] T. J. Ley, P. J. Minx, M. J. Walter, R. E. Ries, H. Sun, M. McLellan, J. F. DiPersio, D. C. Link, M. H. Tomasson, T. A. Graubert, et al. A pilot study of high-throughput, sequence-based mutational profiling of primary human acute myeloid leukemia cell genomes PNAS, November 25, 2003; 100(24): 14275 - 14280. [Abstract] [Full Text] [PDF] G. Xu, M. Nagano, R. Kanezaki, T. Toki, Y. Hayashi, T. Taketani, T. Taki, T. Mitui, K. Koike, K. Kato, et al. Frequent mutations in the GATA-1 gene in the transient myeloproliferative disorder of Down syndrome Blood, October 15, 2003; 102(8): 2960 - 2968. [Abstract] [Full Text] [PDF] M. Libura, V. Asnafi, A. Tu, E. Delabesse, I. Tigaud, F. Cymbalista, A. Bennaceur-Griscelli, P. Villarese, G. Solbu, A. Hagemeijer, et al. FLT3 and MLL intragenic abnormalities in AML reflect a common category of genotoxic stress Blood, September 15, 2003; 102(6): 2198 - 2204. [Abstract] [Full Text] [PDF] Z. Li, J. Yan, C. J. Matheny, T. Corpora, J. Bravo, A. J. Warren, J. H. Bushweller, and N. A. Speck Energetic Contribution of Residues in the Runx1 Runt Domain to DNA Binding J. Biol. Chem., August 29, 2003; 278(35): 33088 - 33096. [Abstract] [Full Text] [PDF] L. Rainis, D. Bercovich, S. Strehl, A. Teigler-Schlegel, B. Stark, J. Trka, N. Amariglio, A. Biondi, I. Muler, G. Rechavi, et al. Mutations in exon 2 of GATA1 are early events in megakaryocytic malignancies associated with trisomy 21 Blood, August 1, 2003; 102(3): 981 - 986. [Abstract] [Full Text] [PDF] H. Hirai Molecular Mechanisms of Myelodysplastic Syndrome Jpn. J. Clin. Oncol., April 1, 2003; 33(4): 153 - 160. [Abstract] [Full Text] [PDF] M. L. Kalev-Zylinska, J. A. Horsfield, M. V. C. Flores, J. H. Postlethwait, M. R. Vitas, A. M. Baas, P. S. Crosier, and K. E. Crosier Runx1 is required for zebrafish blood and vessel development and expression of a human RUNX1-CBF2T1 transgene advances a model for studies of leukemogenesis Development, March 6, 2003; 129(8): 2015 - 2030. [Abstract] [Full Text] [PDF] C. Roumier, V. Eclache, M. Imbert, F. Davi, E. MacIntyre, R. Garand, P. Talmant, P. Lepelley, J. L. Lai, O. Casasnovas, et al. M0 AML, clinical and biologic features of the disease, including AML1 gene mutations: a report of 59 cases by the Groupe Francais d'Hematologie Cellulaire (GFHC) and the Groupe Francais de Cytogenetique Hematologique (GFCH) Blood, February 15, 2003; 101(4): 1277 - 1283. [Abstract] [Full Text] [PDF] H. Harada, Y. Harada, H. Tanaka, A. Kimura, and T. Inaba Implications of somatic mutations in the AML1 gene in radiation-associated and therapy-related myelodysplastic syndrome/acute myeloid leukemia Blood, January 15, 2003; 101(2): 673 - 680. [Abstract] [Full Text] [PDF] P. D. Kottaridis, R. E. Gale, S. E. Langabeer, M. E. Frew, D. T. Bowen, and D. C. Linch Studies of FLT3 mutations in paired presentation and relapse samples from patients with acute myeloid leukemia: implications for the role of FLT3 mutations in leukemogenesis, minimal residual disease detection, and possible therapy with FLT3 inhibitors Blood, September 18, 2002; 100(7): 2393 - 2398. [Abstract] [Full Text] [PDF] B. U. Mueller, T. Pabst, M. Osato, N. Asou, L. M. Johansen, M. D. Minden, G. Behre, W. Hiddemann, Y. Ito, and D. G. Tenen Heterozygous PU.1 mutations are associated with acute myeloid leukemia Blood, July 18, 2002; 100(3): 998 - 1007. [Abstract] [Full Text] [PDF] H. Leroy, C. Roumier, N. Grardel-Duflos, E. Macintyre, P. Lepelley, P. Fenaux, and C. Preudhomme Unlike AML1, CBFbeta gene is not deregulated by point mutations in acute myeloid leukemia and in myelodysplastic syndromes Blood, May 15, 2002; 99(10): 3848 - 3850. [Abstract] [Full Text] [PDF] J. Michaud, F. Wu, M. Osato, G. M. Cottles, M. Yanagida, N. Asou, K. Shigesada, Y. Ito, K. F. Benson, W. H. Raskind, et al. In vitro analyses of known and novel RUNX1/AML1 mutations in dominant familial platelet disorder with predisposition to acute myelogenous leukemia: implications for mechanisms of pathogenesis Blood, February 15, 2002; 99(4): 1364 - 1372. [Abstract] [Full Text] [PDF] A. Buijs, P. Poddighe, R. van Wijk, W. van Solinge, E. Borst, L. Verdonck, A. Hagenbeek, P. Pearson, and H. Lokhorst A novel CBFA2 single-nucleotide mutation in familial platelet disorder with propensity to develop myeloid malignancies Blood, November 1, 2001; 98(9): 2856 - 2858. [Abstract] [Full Text] [PDF] P. D. Kottaridis, R. E. Gale, M. E. Frew, G. Harrison, S. E. Langabeer, A. A. Belton, H. Walker, K. Wheatley, D. T. Bowen, A. K. Burnett, et al. The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials Blood, September 15, 2001; 98(6): 1752 - 1759. [Abstract] [Full Text] [PDF]

	Copyright © 2000 by American Society of Hematology         Online ISSN: 1528-0020